Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells

Journal of Infectious Diseases

Volumn 205, Issue 9, 2012, Pages 1448-1455

  Boudová, Sarah ^a   Li, Haishan ^a   Sajadi, Mohammad M ^a   Redfield, Robert R ^a   David Pauza, C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR GAMMA 2 CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL DESTRUCTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PERSISTENT VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; VIREMIA; VIRUS REPLICATION;

EID: 84861556016     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis217     Document Type: Article

References (46)

1. Demarest JF, Jack N, Cleghorn FR, et al. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 2001; 17:1333-44.
2. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD41 T-cell levels. AIDS 1993; 7:1159-66.
3. Learmont J, Tindall B, Evans L, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340:863-7.
4. Levy JA. HIV pathogenesis and long-term survival. AIDS 1993; 7: 1401-10.
5. Keet IP, Krol A, Klein MR, et al. Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD41cell counts. J Infect Dis 1994; 169:1236-43.
6. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with longterm nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332:209-16.
7. Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007; 21:517-19.
8. Hebbeler AM, Propp N, Cairo C, et al. Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol 2008; 128:349-57.
9. Enders PJ, Yin C, Martini F, et al. HIV-mediated gammadelta T cell depletion is specific for Vgamma21 cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses 2003; 19:21-9.
10. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfield RR, Pauza CD. Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis 2004; 189:1482-6.
11. Riedel DJ, Sajadi MM, Armstrong CL, et al. Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS 2009; 23:1955-64.
12. Li H, Peng H, Ma P, et al. Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China. Clin Infect Dis 2008; 46:1466-72.
13. Lefrere JJ, Morand-Joubert L, Mariotti M, et al. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997; 90:1133-40.
14. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infectionenhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996; 173:60-7.
15. Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J. Neutralizing antibodies are positively associated with CD41 T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998; 12:1591-600.
16. Liegler TJ, Yonemoto W, Elbeik T, Vittinghoff E, Buchbinder SP, Greene WC. Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors. J Infect Dis 1998; 178:669-79.
17. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIVinfected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97:2709-14.
18. Salgado M, Rallon NI, Rodes B, Lopez M, Soriano V, Benito JM. Longterm non-progressors display a greater number of Th17 cells than HIVinfected typical progressors. Clin Immunol 2011; 139:110-4.
19. O'Connor GM, Holmes A, Mulcahy F, Gardiner CM. Natural killer cells from long-term non-progressor HIV patients are characterized by altered phenotype and function. Clin Immunol 2007; 124:277-83.
20. Li H, Pauza CD. HIV envelope-mediated, CCR5/a4b7-dependent killing of CD4-negative cd T cells which are lost during progression to AIDS Blood 2011; 118:5824-31.
21. Cummings JS, Cairo C, Armstrong C, Davis CE, Pauza CD. Impacts of HIV infection on Vgamma2Vdelta2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS. J Leukoc Biol 2008; 84:371-9.
22. Cairo C, Armstrong CL, Cummings JS, et al. Impact of age, gender, and race on circulating gammadelta T cells. Hum Immunol 2010; 71:968-75.
23. Evans PS, Enders PJ, Yin C, Ruckwardt TJ, Malkovsky M, Pauza CD. In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology 2001; 104:19-27.
24. Pantaleo G, Fauci AS. New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995; 13:487-512.
25. Caccamo N, Dieli F, Wesch D, Jomaa H, Eberl M. Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. J Leukoc Biol 2006; 79:663-6.
26. Caccamo N, Meraviglia S, Ferlazzo V, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol 2005; 35:1764-72.
27. Dieli F, Poccia F, Lipp M, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 2003; 198:391-7.
28. Alexander AA, Maniar A, Cummings JS, et al. Isopentenyl pyrophosphate-activated CD561 {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 2008; 14:4232-40.
29. Urban EM, Chapoval AI, Pauza CD. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells. Clin Dev Immunol 2010; 2010:732893.
30. Vieillard V, Fausther-Bovendo H, Samri A, Debre P. Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J Acquir Immune Defic Syndr 2010; 53:564-73.
31. Maniar A, Zhang X, Lin W, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010; 116:1726-33.
32. Chen Z, Freedman MS. CD161 gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis. Clin Immunol 2008; 128:219-27.
33. Tokuyama H, Hagi T, Mattarollo SR, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab. Int J Cancer 2008; 122: 2526-34.
34. Poonia B, Pauza CD. Gamma delta T cells from HIV1 donors can be expanded in vitro by zoledronate/IL-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy 2012; 14:173-81.
35. Tikhonov I, Deetz CO, Paca R, et al. Human Vgamma2Vdelta2 T cells contain cytoplasmic RANTES. Int Immunol 2006; 18:1243-51.
36. Poccia F, Gougeon ML, Agrati C, et al. Innate T-cell immunity in HIV infection: the role of Vgamma9Vdelta2 T lymphocytes. Curr Mol Med 2002; 2:769-81.
37. Ali Z, Yan L, Plagman N, et al. Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits. J Immunol 2009; 183:5407-17.
38. Pauza CD, Riedel DJ, Gilliam BL, Redfield RR. Targeting gammadelta T cells for immunotherapy of HIV disease. Future Virol 2011; 6:73-84.
39. Das H, Wang L, Kamath A, Bukowski JF. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001; 98:1616-18.
40. Keller RK, Fliesler SJ. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem Biophys Res Commun 1999; 266:560-3.
41. Meraviglia S, Eberl M, Vermijlen D, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010; 161:290-7.
42. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 2010; 30:575-9.
43. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67:7450-7.
44. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102:200-6.
45. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96:384-92.
46. Poccia F, Gioia C, Martini F, et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS 2009; 23:555-65.